1.95
+0.11(+5.98%)
Currency In USD
| Previous Close | 1.84 |
| Open | 1.9 |
| Day High | 1.98 |
| Day Low | 1.83 |
| 52-Week High | 16.27 |
| 52-Week Low | 1.61 |
| Volume | 764,485 |
| Average Volume | 1.91M |
| Market Cap | 138.97M |
| PE | -0.78 |
| EPS | -2.5 |
| Moving Average 50 Days | 2.32 |
| Moving Average 200 Days | 3.88 |
| Change | 0.11 |
If you invested $1000 in Zentalis Pharmaceuticals, Inc. (ZNTL) since IPO date, it would be worth $84.05 as of March 12, 2025 at a share price of $1.95. Whereas If you bought $1000 worth of Zentalis Pharmaceuticals, Inc. (ZNTL) shares 3 years ago, it would be worth $46.9 as of March 12, 2025 at a share price of $1.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
GlobeNewswire Inc.
Mar 03, 2025 1:00 PM GMT
Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zenta
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 9:05 PM GMT
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and ot
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 03, 2025 10:42 PM GMT
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biologica